Sylvester study addresses one of the major mechanisms of pancreatic cancer treatment resistance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown for the first time that a combination of targeted therapies with immunotherapy addresses a major cause of treatment resistance in pancreatic cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Marlon L. Wong, associate professor of clinical physical therapy at the University of Miami Miller School of Medicine, was awarded a grant from Gabrielle’s Angel Foundation for Cancer Research. The three-year, $225,000 award will support research focused on improving quality of life for patients living with chemotherapy-induced peripheral neuropathy and other long-term effects of cancer treatment.
Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login